BSECompany Update1d ago · 4 Sept 2026, 03:01 pm
Please refer attached pdf.
Ind-Swift Laboratories Ltd · 532305
✦ AI SummaryFundraise
Ind-Swift Laboratories Ltd has announced the outcome of its Preferential Issue Committee meeting, where the committee has taken note of the revised valuation report and made changes to the Explanatory Statement to the Extra-Ordinary General Meeting Notice. The company has decided to issue warrants at an issue price of Rs. 196/- each, which is higher than the minimum issue price of Rs. 195.98/- each.
Analysis Scores
Earnings Impact2/10
Growth Catalyst3/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Ind-Swift Laboratories Ltd - 532305 - Outcome Of Preferential Issue Committee Meeting Held On Friday, 4Th September, 2026, As Per Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Attachments (1)
📄pdf
Download →
7c1377f3-a1c3-42bd-9b87-23f334ed9fce.pdf
View document text
Date: September 04, 2026
To, To,
Corporate Relationship Department Listing Compliance Department
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor, Plot No. C/2,
25th Floor, Dalal Street, G-Block, Bandra Kurla Complex, Bandra (E),
Mumbai – 400001, India Mumbai – 400051, India
Scrip Code: 532305 Symbol: INDSWFTLAB
Subject : Outcome of Preferential Issue Committee meeting held on Friday, 4th September, 2026,
as per Regulation 30 of Securities and Exchange Board of India (Listing Obligations and
Disclosure Requirements) Regulations, 2015.
Reference : Outcome of the Board Meeting held on Friday, July 10, 2026, and Preferential Issue
Committee held on Wednesday, July 29, 2026.
Dear Sir/Ma’am,
In reference to the captioned subject and further to our intimation of the outcome of the meeting of the Board
of Directors of Ind-Swift Laboratories Limited (“the Company”) held on Friday, July 10, 2026 (“Board
Meeting Outcome”) and the meeting of the Preferential Issue Committee held on Wednesday, July 29, 2026
(“Committee Meeting Outcome”), the Notice of Extra-Ordinary General Meeting dated July 10, 2026 (“EGM
Notice”), read with Corrigendum thereto dated Wednesday, July 29, 2026 (“Corrigendum”), in relation to the
Extra-Ordinary General Meeting held on Wednesday, August 05, 2026 (“EGM”), and pursuant to the
deliberations with the Stock Exchanges (NSE) we wish to inform you that the members of the Preferential Issue
Committee of the Board of Directors of the Company, at their meeting held today, i.e. Friday, September 04,
2026, have taken note of the revised valuation report from the valuer and the following changes in the
Explanatory Statement to the aforesaid EGM Notice and Corrigendum:
Point No. XII of the Explanatory Statement to the EGM Notice shall be substituted and read as under:
“Issue price and Relevant Date:
In terms of Regulation 161 of SEBI ICDR Regulations, 2018, the relevant date for determining the floor price
for the Preferential Allotment of the Warrants has been reckoned as Monday, July 06, 2026, being the date 30
days prior to the date of Extra-ordinary General Meeting i.e. Wednesday, August 05, 2026. The Equity Shares
of the Company are listed on National Stock Exchange of India Limited (“NSE”) and BSE Limited (“BSE”).
The Equity Shares of the Company are frequently traded within the meaning of explanation provided in
Regulation 164(5) of Chapter V of the SEBI ICDR Regulations, 2018 and NSE being the Stock Exchange with
higher trading volumes for the said period, has been considered for pricing in compliance with Regulation 164
of Chapter V of the SEBI ICDR Regulations, 2018.
Further, in compliance with Regulation 166A of the ICDR Regulations as the preferential issue to the allottee,
is for more than five per cent of the post issue fully diluted share capital of the Company, therefore, the minimum
issue price shall be the higher of the price determined through following methods:
1. In terms of Regulation 164 of Chapter V of the SEBI ICDR Regulations, the minimum price at which
Warrants are to be issued shall not be less than higher of the following:
a) Rs. 154.48/- each – being the Average of 90 Trading days volume weighted average price of the equity
shares of the Company quoted on the Stock Exchange preceding the Relevant Date; or
b) Rs. 195.98/- each – being the Average of 10 Trading days volume weighted average price of the equity
shares of the Company quoted on the Stock Exchange preceding the Relevant Date.
Accordingly, the minimum issue price in terms of Regulation 164 of the SEBI (ICDR) Regulation, is Rs.
195.98/- (Rupees One Hundred Ninety-Five and Ninety-Eight Paisa Only) each, being higher of the
above two prices.
2. Price as determined in accordance with the methodology prescribed in the Articles of Association of the
Company: Not Applicable as the Articles of Association of the Company are silent on the determination of
a floor price/ minimum price of the shares issued on preferential basis;
3. The price determined through Valuation report of Corporate Professionals Valuation Services
Private Limited having Registration No. IBBI/RV-E/02/2019/106, is Rs. 189.46/- each. The said report
is available on the website of the Company at Preferential Issue - Ind-Swift Group.
Accordingly, the minimum issue price of Warrants on Preferential basis shall be Rs. 195.98/- each. However,
the Board of Directors of the Company has decided to issue the Warrants, at an Issue Price of Rs. 196/- (Rupees
One Hundred and Ninety-Six Only) each, which is higher than the above-mentioned prices.”
All other particulars and details in the EGM Notice and Corrigendum remain the same and unchanged.
The Meeting commenced at 02:00 P.M. and concluded at 02:30 P.M.
You are requested to take the same on your record.
For Ind-Swift Laboratories Limited
Pardeep Verma
VP - Corporate Affairs & Company Secretary